Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;34(12):1882-1890.
doi: 10.1002/mds.27848. Epub 2019 Sep 10.

Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism

Tung-Hung Su  1   2 , Hung-Chih Yang  1 , Tai-Chung Tseng  1   2 , Shih-Wan Chou  1 , Chin-Hsien Lin  3 , Chen-Hua Liu  1   2 , Chun-Jen Liu  1   2 , Chi-Ling Chen  4 , Jia-Horng Kao  1   2   4   5
Affiliations

Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism

Tung-Hung Su et al. Mov Disord. 2019 Dec.

Abstract

Background: The risk of parkinsonism after antiviral treatment against chronic hepatitis C (CHC) is unclear.

Objectives: To investigate the association between CHC and parkinsonism and the efficacy of antiviral therapy.

Methods: Using the National Health Insurance Research Database of Taiwan from 2004 to 2012, patients with and without CHC, patients receiving pegylated interferon-based antiviral therapy, and those without such therapy were matched by age, gender, and comorbidities by propensity scores and followed for new diagnoses of parkinsonism and Parkinson's disease (PD). Multivariable Cox proportional hazards regression analyses were performed.

Results: Overall, 49,342 patients with CHC were matched with 49,342 non-CHC patients. After adjustment for confounding factors, there was a significantly increased risk (31%) of parkinsonism (hazard ratio [HR] 1.306; 95% confidence interval [CI], 1.208-1.412) in those with CHC and the risk of parkinsonism requiring anti-Parkinson medication (HR 1.323; 95% CI, 1.214-1.441). Furthermore, 23,647 untreated CHC patients were matched with 23,647 patients receiving antiviral therapy. Patients receiving antiviral therapy had a significantly lower risk of developing parkinsonism (38%; HR 0.618; 95% CI, 0.498-0.765) and a reduced risk of parkinsonism requiring anti-Parkinson medication (HR 0.651; 95% CI, 0.515-0.823). In sensitivity analyses, antiviral therapy significantly reduced the risk of parkinsonism and PD after adjustment for detection, selection, disease latency biases, and competing mortality. Our results suggest successful antiviral therapy associates with a reduced risk of hepatitis C virus-related parkinsonism compared with those with treatment failure.

Conclusions: CHC infection is associated with an increased risk of parkinsonism or PD. Antiviral therapy against CHC is associated with a reduced risk of parkinsonism or PD. © 2019 International Parkinson and Movement Disorder Society.

Keywords: HCV; Parkinson's disease; direct antiviral agent; movement disorder; pegylated interferon.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 2016;15(12):1257-1272.
    1. Liu W-M, Wu R-M, Lin J-W, Liu Y-C, Chang C-H, Lin C-H. Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: a nationwide, population-based study. J Formos Med Assoc 2016;115(7):531-538.
    1. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers 2017;3:17013.
    1. Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012;2(8):a009258.
    1. Jang H, Boltz DA, Webster RG, Smeyne RJ. Viral parkinsonism. Biochim Biophys Acta 2009;1792(7):714-721.

Publication types

LinkOut - more resources